Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsBristol Myers Squibb maintains a deep portfolio of oncology and immunology treatments while generating high levels of free cash flow.

Read the original report for the complete account of this story.